ProteoGenix - The New Era: Fall 2002

Eli Lilly and Company

ProteoGenix Signs Research Agreement with Eli Lilly and Company to Study Proteomics in Children with Short Stature - November 23, 2004

Dr. Ron Rosenfeld, CEO of ProteoGenix, announced that five-year research agreement was signed between ProteoGenix, Inc. and Eli Lilly and Company. The agreement calls for scientists at ProteoGenix, lead by Dr. Srinivassa Nagalla, to evaluate novel proteins and peptides that may aid in the diagnosis and treatment of idiopathic short stature (ISS) in children. The term "idiopathic" means that the cause of the delayed growth is unknown.

ProteoGenix and Lilly hopeto discover new and unique proteins that may serve as a diagnostic markers to help identify which children have ISS, may also reveal the cause of short stature in these children, and help pediatricians in determining the best treatment.

© Copyright 2005-2007. All rights reserved.

Proteogenix

Careers at ProteoGenix Director, Human Resources Director, Immunodiagnostics Product Development Research Associate, Immunodiagnostics Product Development

Management Board of Directors Research Staff

Intra-amniotic Infection Pre-term Birth Down Syndrome

Oregon Health & Science University Beckman Coulter Eli Lilly

Genomics Proteomics Metabolomics Bioinformatics

ProteoGenix Publishes Four Landmark Articles on Diagnostic Applications for Pregnancy (Journal of Proteome Research, April 2007) ProteoGenix Receives Best Clinical Study Award at SMFM Annual Meeting for Preterm Birth and Intra-amniotic Infection (February 2007) ProteoGenix Publishes Identification of Novel Biomarkers in Cervical-Vaginal Fluid for Noninvasive Detection of Intra-amniotic Infection (Journal of Proteome Research, January 2007) Test May Prevent Premature Births (BBC, July 2004) Discovery Could Help Prevent Premature Births (CNN and Associated Press, July 2004) Protein Linked to Premature Births (MSNBC and Associated Press, July 2004) OHSU test targets premature births: Scientists are developing a simple blood screening that could cut the number of risky early births nearly in half. (The Oregonian, July 2004) ProteoGenix Publishes Key Study of Intra-amniotic Infection (Journal of the American Medical Association, July 2004) ProteoGenix Scientists Describe Novel Mass Spec Algorithm (Analytical Chemistry, July 2004) ProteoGenix Receives NIH SBIR Award for "Diagnositic proteiomic profiles for aneuploidy" November 2003

Investor Information Contact Information